6 Quotes by Keay Nakae

Obviously, the Guidant board favors the certainty associated with J&J's offer. They've basically gotten the FTC to sign off with J&J. They just need shareholder approval.

If Boston Scientific is to come back, they will have to come back north of US$75 to keep this alive. They'll have to come back at least US$2 or more higher than they were.

The overall number where there is actually a problem is still low, but more importantly, you've got, once again, a revelation that the problem is a little wider than first thought. What people had been hoping to see is some end to this.

It seems like Boston Scientific really wants this deal and will pull out all the stops to get it. It's a very rare asset. Cardiac rhythm management has $10 billion and only three companies.

The gold standard, if you will, is being able to have a label on the product that says it's sterile.

The cardiac rhythm management business is large -- $10 billion, highly profitable and it's an oligopoly.